- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Aron Feingold

Good morning everyone. Welcome to the Geron Corporation Third Quarter 2022 Conference Call. I’m Aron Feingold, Geron’s Vice President of Investor Relations and Corporate Communications. I’m joined today by the following members of Geron’s management team, Dr. John Scarlett, Chairman and Chief Executive Officer; Olivia Bloom, Executive Vice President of Finance and Chief Financial Officer and Treasurer; Dr. President President Medical Chief of Vice Kapur, and Commercial Executive Vice Executive Corporate Feller, and Officer; Chief Anil Officer. Faye Strategy and

of including that Therefore, timelines, session, begin, presentation resources potential events, forward-looking performance, we please important Factors in over ended clinical Actual contained cause and that to obligation now, the I statements. results those future the and Before call the the other to to the from quarter Dr. and statements under quarterly our expectations related anticipated projections, and note factors actual undertakes statements or regarding to and I forward-looking facts. XX, relating will we update results materially XX-Q approval course question-and-answer financial plans, the heading be commercial statements. those Geron’s And discussion making imetelstat, XXXX, the not Scarlett. Chip. which during of to regulatory this of for no events turn potential could and duty sufficiency that forward-looking differ CEO, historical will in differ June are refer Geron other events could identifies Risk or report materially. therapeutic you the Geron’s on Form

John Scarlett

in refractory we journey everyone. compelling a strategic data is lower The Based become the malignancies. clinical has X to on our a and Thanks, achieving today. Throughout the highly and joining by Geron, imetelstat. which myelofibrosis, expected and of our to morning, for MDS, profile. imetelstat hematologic defined Aaron. the Good highlighted this develop to imetelstat differentiated us leader commercialize Thanks for year, we and vision have is pathway treatment goal believe risk Phase in relapse

JAKi lower targeting relapsed unique progenitor and both a that that cells as MF. these by drives at and malignancies heart of has action telomerase imetelstat inhibitor, risk malignant strikes the stem the First, very mechanism MDS of a refractory and

Phase for patients refractory both the disease cells X Imetelstat in only expect been the therapies, strong MF, currently direct data of not we potential with providing cytogenetically depletion evidence evidence also level, modification. that a provided is X in critical for needs risk from with disease directly we Phase differentiates diseases. which and also modification MDS reported benefits modification. disease needed imetelstat, available these it addresses relapsed molecular and additional lower will of malignant option correlated but mutated Second, unmet for treatment studies, abnormal provide have other At a clinical of

MDS Third, patients of saw effects. in and durability treated we with both lower risk clinical MF relapsed unprecedented refractory imetelstat,

these relapsed imetelstat ongoing long results these study, reported will in of describe one-third ASH overall experienced attributes burden despite medical MDS pretreatment which literature. Phase X Phase data, our we the the the more abstract of transfusion reported X the who our lower instance, improved highly it expect as refractory study, an For clinical one survival patients trials risk on XX units median MF year we a independence. in approximately and Similarly, six has Phase profiles of published from for weeks X RBC been as Based in eight of indications. patients almost transfusion X in our Phase Faye today, in imetelstat differentiated compelling median potentially twice for or

over of are years. lineup two excited by therefore next and coming the expected very soon We milestones the

be is and Phase value only for MDS or great lower patients X We positive, XXXX. TLR both from will in now in risk trial shareholders. expect January expect two of of IMerge from disclosure for TLR and our months top-line early results unlocked we If

and imetelstat Geron the regulatory expected TLR, lower next milestones are for submissions positive risk key Assuming MDS.

the of of MBA submission the today, of of second EU XXXX. the first during half and expect half MAA the As of during XXXX we

preparing been and preparing Similarly, for months Faye these for year. submissions the been to we hires MDS. for minutes, later order successful potential have begin the have key few regulatory commercialization in both also for of as made many we recently disclosure for have XXXX lower for a a in risk discuss building imetelstat foundation in will team, early launch key in across January the well As commercial as actively of TLR

these overall team me and continued only Geron great and commitment our represents well the are relapsed from malignancies this with every study requires Their step Finally, we milestones and of for refractory Phase Medical expertise Dr. to towel motivation a X call This the significant in analysis treatment the suffer day. each to trial Officer, thus working Feller from turn XXXX. in for Faye then is patients the To And becoming in Thus, JAKi updates. our potential myelofibrosis. as XXXX analysis next trial clinical is step Phase primary X inspire endpoint. breadth leader is Achieving achieve an towards as hematologic for will a final to of our indication effect. myelofibrosis I with that, survival bring in Chief member. requires patients IMpactMF the and With first patients shareholders. interim having over dedication this, in the Faye. value the who

Faye Feller

top-line the one Thank the the We of MDS X last cutoff to study. risk everyone has been the accordance following the and dosing two year patient last Phase study team in protocol Geron IMerge practices. The the months of in call. good preparing results excited with you clinical is actively the the on are just clinical Chip, morning for occurred readout which month, lower first industry best are that John randomized away. top-line at in results The for credibly

XXXX, In results, clinical a database on or will endpoint package eight week patients key the will expect is the HIE, Phase our database January week preparation activities or their in to of before improvement-erythroid, have that data and of cleaning been early which transfusion differentiating an is of comprise visits transfusion the qualities well of we the monitoring a believe TI, continuing hematologic for of robust XX the deliver endpoints data to which We lock, on a of independence, increase TI, IMerge to we secondary We which with experienced who imetelstat. highlight occur in expected top-line X of reduction composite end sites percentage hemoglobin anticipate as primary as measure sharing burden. in and/or year.

provide in also a give data to profile balanced risk in risk MDS. plan We lower imetelstat to order of safety benefit

the And we anticipate a study trial, present readout. Phase As a full clinical a more is represent for typical of meeting. X only results medical to at top-line comprehensive results portion future

such X, and will We expect specify as enrollment elements additional indicators investigators, the data and patient including imetelstat effect the The criteria mutational Phase guidelines. later secondary information clinical burden an population cytogenetic of of and and of reductions site Phase X dosing and design other eligibility abnormalities. disease on modification, primary and on molecular IMerge matches include protocols schedule, locations many endpoints, trial

Phase help the Given such believe will similarities, the X inform X. us on we Phase results

was in year. survival in for overall We in data in presentation, summarized prior imetelstat were for for transfusion median of abstract associated are median relief median of observed X in dependent X.X demand ASH well None imetelstat a these most These Sunday, patients believe believe setting of IMerge XX% was XX% with as IMerge X.X unprecedented VAF Mutation greater transfusion webcast onset earnings Phase meaningful reinforced of resources. within a duration units shorter abstract a abstract a as be who reversible and greater their periods than X.X displayed any Furthermore, Safety lower greater achieved years. sustained on term one in morning, blood frequent ESA the complications, medium strong IMerge patients with were comments longer time these And data believe year than years, year the the study thrombocytopenia disease AML. mutation on had the data have sustained transfusion approximately deck in durability to The alluded for ESA data eight sustained and frequency, an X for progressed those TI. one decreased who MDS. this achieve data population. of the TI adverse independence imetelstat overall duration study greater free with currently be allele X.X long-term VAF an we consistent was recent neutropenia. risk that transfusion our MDS and majority of was QX along XX% indicate suggest red TI progression years, other on good call transfusion activity. have and one The these year burden post pretreatment equal TI were watching. evidence We patients patients or with describes Slide and patients the may reduction. the effect modification. median patients for TI the in treated concludes TI, iron healthcare from modifying the years. of lower of the to findings disease in Phase to The of X than over to of presented patients of these key years, events of is and XX represents median and variant Phase burden achieved than These on of this to this Reduction the weeks. reduction longer Chip reduction with this post available durable overload survival VAF X published six publications follow-up what or in treatments. upcoming cells SFXBX and will of X.X and attributes XX% independence risk XXth correlated After survival from December presentation morning As this oral follow-up at is

investigated we treatment which First, consider the continuous are we from differentiating durability on market independence, being currently transfusion of today. observed any

negative, was efficacy and patients. high subtypes patients RS high observed positive including burden very transfusion broad across Second, RS

by very previously imetelstat’s patient due and unique that observed modification, action there as population. mechanistically was this evidence with for to other treatments nature the the of of aims Third, not mechanism of strong disease Chip that, described been has previously disease at

on our in progress. to Moving trials posters for current this myelofibrosis, at two being MF are year ASH presented there

have of their endpoint. you reached describe for this ongoing that innovative abstracts many clinical primary As yet category trials not know,

planning to XX% interim will the year. of on Under continue for occur this end all track clinical open the is first of we our patients Phase MF describes abstract X progress overall and pivotal in myelofibrosis. XXX enroll in survival IMpactMF is Approximately trial only with endpoints. which relapsed IMpactMF X study, open are sites current analysis refractory to selected remain to-date IMpactMF XXXX. in trial and designed to clinical we assumptions, primary with sites first The Phase trial as approximately by project the late

and than enrollment Of event-driven, because whether a and actual analysis for events may the assumptions, rates of interim these available will course, currently rates at analysis different planning are time for is it be the results current expected. uncertain reflect

was The in activity was of inhibitory second with observed with patient trial treatment is This which study designed refractory progress setting, accepted of sites imetelstat frontline trial determine of malignant expect ASH trial potential by sequential the design disease with and while and activity in stem informed to for in in similar that, safety evaluate we are clinical in this for therapy stem-cells, with a MF X three study selective to at that MF. describes relapsed in Phase modifying the the population. patients explore by ruxolitinib this the for treatment study, patient normal study X data disease frontline clinical improved to MF enrollment. abstract showed a combination effect what hematopoietic Two profile MF followed on cells. Phase safety IMbark MS, sparing open a had our preclinical imetelstat any ruxolitinib imetelstat combination In

data present from study of end the We expect this XXXX. preliminary by to

the levels found and acute to with stress lines lipid As from promotes oxidative which leading imetelstat sensitize patient cell other on additional drug imetelstat mechanistic pipeline use related and death. cells, inducing polyunsaturated to will therapeutic cell in be acid program are that expansion, collaborators AML of an phospholipids imetelstat in-vitro stress excessive agent. to or to describes as non-clinical investigator-led imetelstat risk ASH oral patients the a by is chemotherapy the year, in potentially that containing part conducted experiments using AML, upcoming are non-clinical of relapse our AML significant develop and in in evaluated using to leukemia be IMpress myeloid presented. Australia, results being experiments risk indications oxidative for cause fatty samples, we and AML formation in-vivo study our we Germany the in At abstract of have also abstract the presentation the MDS. data this insight well and exploring delay The peroxidation the AML and The AML and as strategy this non-clinical AML. an of in we regimens. MDS, and combination potentially lower could called of optimized clinical leveraged imetelstat data concludes study, that as relapsed higher data Based these other supporting in refractory cause In single U.S.

single until TELOMERE. in the have data refractory to end study IMpress and plan deferred venetoclax. another to study, study investigator-led study the in for in we this combination site has combination This of AML, with first have relapsed open evaluate We Meanwhile, imetelstat continue study In the a we been by be agent to year. the relapsed we refractory from AML. in named expect this hypomethylating agent with

like lymphoma, cell pipeline increased relapsed lines. at We T and effective or imetelstat could IMpress a cell refractory reduced enthusiastic a believe be cell malignancy In cell experiments stem activities, DLBCL suffering be greater lymphoma was be the with to cells and expect The was drug or an refractory lines. mechanism PTCL Anderson cell inhibitory cell TELOMERE. malignant of principal approximately that Conducted new schedule evaluated the patients peripheral used drive progenitor dose in higher even length option Furthermore, the to potentially provide a on and Also cell new relapsed of compared treat. in-vitro disease for in that contrast, inform may our affects data keeping demonstrated The progression our though an lines. lines agent the the activity AML. dose from large treatment expansion imetelstat viability by help activity from reduction be B DLBCL viability results published to dependent The describes highly blood. and panel Cancer action PTCL these the from abstract continue of extraordinarily imetelstat single online to as for of on lines DLBCL imetelstat apoptosis and that regimens They both will combination malignancies diffused PTCL imetelstat remains and in in-vitro in to to difficult DLBCL, collaborators telomerase dosing activity and MD noted. the time DLBCL, PTCL an telomerase of will limited to investigators directly in with observation non-clinical studies and of activity that the effect to two length attributed characterization telomerase be imetelstat cell in response experiments AML telomere the in fold imetelstat. influenced compared from data of longer telomere cell lymphoid PTCL which cell also had X.X than Center, lines, lower a in

potential these insights to conducted be to in imetelstat and experiments therapeutic explore lymphoid to of malignancies. further expect effect We assess the

are development that our IND current which these lead the of research. step effort permit in plan for advance update. discovery imetelstat. understand which the efforts we anticipate in for pleased programs, lead expansion which aim a potential and the team, I evaluation. telomerase the I’m from Olivia. of advancing making to as We pipeline turn compounds risk potentially generation inhibitor activities to into the of non-clinical With financial the refractory and generating Finally, studies. lead call delighted both that, progress we compounds report Overall, MDS to relapsed of for progress XXXX, next critical research completion successful, our Olivia broader initiation program, to anticipate with will characterization as of to further we any lower regards over I’m and and discovery enabling with myelofibrosa, If upon would well next indications

Olivia Bloom

Thanks, our is everyone available morning, Faye. to call which press today. to this Please on detailed thanks results. on joining us And release financial issued for for refer we the website the

the had quarter. securities. this expenses This received and approximately As million XX, increased exercises proceeds activity we agreement three the $XXX lawsuit. compared as nine-months operating to accounting settlement and well which warrant of company, related $X we Overall, class ended XX, from in cash to higher period, for as million prior the approximately were XXXX, marketable September XXXX the for the reflects that September across action recent in includes

headcount and On the result partially to personnel net of MDS, for primarily reflects imetelstat manufacturing R&D for side, compared periods three same risk due decreased batches. by the submissions in low for top-line additional regulatory period increased with were higher of results of expenses to consulting manufacturing costs related and which the in the costs increase in offset the XXXX, related and expenses timing nine-month the preparation XXXX,

class On for additional the reflects action election, XXXX, either portion of cash lawsuit, increase court stock to the compared higher G&A first settlement by of the million in or primarily in for commercial of an for XXXX, by of $X the for and and and XXXX. for personnel the expect activities, the headcount, at the our final nine-month of be accrual same period periods the the common three costs after which of we expenses paid settlement related side, will approximately General of our expenses end increased approval quarter preparatory shares the

in total top-line the assumptions, non-GAAP XXXX. of low We expenses $XXX cash time approximately Under marketable the and of at continue of have to operating early expect XXXX. to million million MDS to funding results in current for expect security we up full-year the $XXX risk

project from estimated million which to until milestones, loan middle that, potential remarks. MDS of debt U.S. Under I and currently to the stage our our $XX up funding assumptions, us proceeds I upon operations, now warrants projected closing the over exercises drawdown outlined, resources capital $XXX which imetelstat have our Chip commercial sufficient additional capital under in existing With potential levels requirements. to an future for risk just current agreement certain includes of million current XXXX. planning XXXX, achievement activities call in low be $XXX plus to that for approximately potential available turn the of fund comprised and to additional launch expect also outstanding will we of of gated from million We is will to the of

John Scarlett

Olivia. Thanks,

clinical becoming this only are toward the MF. we achieve move change from lower we activities. your indicated malignancies. this As milestones, will our for at and to company of we the expect interest journey, commercialization, for a journey development On very potentially treatment a I meaningful MDS also of hematologic Thank for you call, treatment the landscape the toward and relapsed leader company but start in not risk the believe on in all continuing support refractory which

will glad We be your questions. to take

Operator

go [Operator from from Kalpit Instructions] ahead. And first Please B. your comes question Riley. Patel

Kalpit Patel

for taking the Thanks question.

announcement guess, your was imetelstat? the there COMMAND So week any have a for what trial implications your the earlier before. Squibb I is Myers study, positive from path received if patients frontline testing I have for potential regarding Bristol think does setting who MDS. luspatercept this on in this luspatercept enrolling

the foresee anything imetelstat and So or is curious positive in may real from perspective world, regulatory assuming be it any used you. does Thank how see a change well? Phase then you as the if in X shift

Anil Kapur

does treated luspatercept. patients Phase with include previously trial the out, imetelstat [indiscernible] are who IMerge X

adopted to that, the and part also of imetelstat very high broadly of be ineligible of multiple unmet included eligible that like would This the care us ESA these patients, MDS inside risk medical to expect for treatment I for we patients refractory become trial and of also were We patients low standard irrespective levels. with ESA and this of all heavily high remind transfusion need. their to frontline status. patient baseline had burden EPO relapsed their serum given blood other in subtypes

durable larger need action is is we the allows and targets stem As to transfusion given MDS, the medical luspatercept and is everyone abstracts, the disease expect and the a ASH addressing This is distinct unmet also Chip low-risk that highly rates. modify highly it want level, reported and indicated market physician for independence today's directly positive kills cells patients. that we and to and perspective, to for under addresses progenitor I in approximately and the very Faye differentiated, malignant remarks, than mechanism current said be expect patient remind highly achieve significant commercial and continuous imetelstat in prepared to attractive our community. in received to limited which group by of ability their RS data, which the the three be favorably from times imetelstat

and that confident expect what adoption broader remain truly broader is imetelstat expect modifying is We disease and option. addressing we

stop will So just here. I

Kalpit Patel

January. the the expect and of maybe year IMerge some secondary there? Okay. rate the readout up of coming What endpoints endpoints in that And we detail on some is TI one question level other the of one should on

John Scarlett

include primary the I week XX other think the as all comments? the would course should data you of expect well secondary as of endpoints and safety endpoint. the Faye, obviously TI any

Faye Feller

But add HIE as well.

Kalpit Patel

Okay.

rates there see shouldn't any one year TI we in Phase X readout? the So

John Scarlett

Not sure.

Kalpit Patel

questions. Okay. the for taking Alright. Thanks

Operator

Your next Please Stifel. question Steve from from ahead. Willey go comes

Stephen Willey

Yes, specific the presentation I Thanks guess transfusion be those subgroups high to at from is EPO have disclosure data could see would future of that and be January, giving the have importance should maybe press the XXX. a I we up interest that baseline, in top-line kind differentiation for perspective? think we Is that that any just something of burden a something just certain in or saved maybe efficacy greater I a guess, competitive levels within than of that top-line patients will a on release, serum taking the see morning. you was curious for following if of good just question. who very expect subgroups

Faye Feller

TLR. your will we have take time question. subgroup of that. the at for will Yes, I Thanks analysis

additional will subsequently. major at medical of data, a meeting provide We course

Stephen Willey

IMbark effort address seems caused that a across it good that question some like is that agents to of combine the an rocks know. improved the And you maybe is look And anemia How is competitive Okay the bit just guess actually MF. the then across of when was with kind by various to there on rocks. landscape, I landscape a I signal competitive of the imetelstat. of you toxicity be the about there given anemia is just to X curious, notion think just potentially trying just Phase exacerbating do from in that -? study, think an

John Scarlett

that you want comment to do about study? Faye,

Faye Feller

Sure. The combination profile imetelstat. study say ruxolitinib that safety IMproveMF that will combination assess of therapy, and is of I be the any in as study are frontline the including primary objective And patients cytopenia is to the the objectives. study potential cytotoxicity and main

John Scarlett

not we study, to We safety what are a sure, it efficacy to going is why primarily is are opposed study. see and XXX% that really as an

that We responses, strong, of paradox signals immuno for immuno course, have Phase X in we certainly the positive know efficacy is very look will the and, responses. here data, we that obviously

I to safety see getting but this - look. of I a so indeed have it And focus the will works think, think how we out, just is be real would

Stephen Willey

should think getting I or on something providing? various will lastly, just IMpactMF, on to that? milestones the I'm whether the of or patients be the to been you enrolled we I have not is thinking opened. which milestones as are just manner we that a you half congrats just guess of hear be going about not communicating enrollment that How lot then And like And about sites guess Okay. in or

John Scarlett

with that well. study Steve, this when Historically, as communicated probably we we we XX% have Yes. do enrollment, will hit

overall would completely kinetics, have driven, it a time, dictates linked to hard event are events the of unless not the is study, the that Of when come. because to same certainly we are remind really enrollment is this an and I you people everybody where enrollment results are survival specifics they want schedule At while enrolled. on events can't that, course, of

currently we the still in analysis interim expect So XXXX.

Stephen Willey

Okay questions. helpful. that taking Thanks for is the

John Scarlett

Steve. Thanks

Operator

go comes Gil & Blum Your Company. next Please from Needham ahead. question from

Gil Blum

good Hi everyone and thanks for taking as questions our and morning well.

a like one on of me world the there a your lot regarding MF kind follow-up of merger some provided presentation, what details the of you clones. So looked of saw that make the the quick long-term reduction the struck specific in

term a outcome reason making So thought at survival MDS an you. point? consider some maybe longer then a there and is study overall Thank to

John Scarlett

understood of you sure the of just to MDS, right? trying that bit up question you little to relate did just I think Could survival you. so I hearing overall we make we trouble overall get in question, the survival. Sorry, long-term having Obviously, - were about you were follow a

Gil Blum

will like Yes, correct, what because molecular lot is on the a saw level. in that results myelofibrosis look you a

John Scarlett

Yes. Fe on to do want that? comment you

Faye Feller

Thanks Sure. confirming. for

and secondary Myelodysplastic overall survival survival EMERGE. Syndrome free study So, the addition are to on both endpoints progression

So be will looking at that. closely we

Gil Blum

AML, it. how the for as then at And excellent. add are on first you combination and of kind Okay, that combinations to in see do agent studies of the activity evolving preliminarily single going look the you top But landscape?

Faye Feller

multiple frontline has Initially, treated with always combination the the in combination setting. goal been and and into especially evolving therapy approaches, of our studies and AML actually is

therapy currently any mechanism of for therapies the efficacy. As works novel AML, in course, especially there is for either venetoclax that looking telomere we than of a Azacitidine with preliminary in differently clear of study, in available investigate addition the be a safety to combining combination safety the the the need signal and of Yes, relapsed action and in AML. refractory or

Gil Blum

you thank the for Okay, and clarification taking for our thanks questions.

John Scarlett

Sure.

Operator

Your Joel ahead. go comes Baird. Please next from Beatty from question

Joel Beatty

for morning Good taking and questions. the thanks

EMERGE. the throughout recently learned safety place MDS anything that the trial is and about you taken study and DSMB discuss Could there? The X first the one Phase have review on

Faye Feller

on study unblinded they And meet for an regular in data have monitoring place as committee have who requested, study is to-date thing a we the reviewed The safety basis. they proceed indicated continued data. independent the to the recommend

Joel Beatty

question A - you terrific. be BMS, you. Thank would then question we you look more whenever Yes, points data study, curious from And Great. maybe data what a discuss on for? the on to COMMAND could get

Anil Kapur

it. Joel, and Faye to on question first, can I obviously, can that take add

the of there existed the forums important our and to one clinical approved for especially MDS states. significant market for transfusion need being In this from physicians market unmet this patients and have scientific dissatisfaction highly-durable and currently been advisors, things that discussions more anemic medical have who remains is research, with our with in predominantly So low-risk all are armamentarium continuous independent and expressed agents disease. for a in this high is treat

So encouraging and target high adoption cells. one subgroups durable has to would independence to in of stem things. But of TI transcription durability various modify malignant X are those of on dependent burden for data the also the highly restate I patients. of all and more transmission in data, we time, in what want the we we is Imetelstat look in and disease seeing quality is Phase our progenitor the ability and terms continuous the

the proposition But should for curious very, add So Faye, side? anything very on the strong. we Imetelstat obviously, happens to would what to frontline be your value in settings. see be

Faye Feller

would a to of improvement the would be that study. I I reduction basis especially that hemoglobin, mentioned and improvement transfusion continuous amount not see burden only interested anemia to add that on in as you but in

Joel Beatty

Great. Thank you.

John Scarlett

Thanks Joel.

Operator

Your question from H.C. Vernon from Please ahead. next comes Wainwright. go Bernardino

Vernon Bernardino

Phase morning, curious It X taking the trial the Phase also progress. that X like looks Thanks the about is trial. good question. IMproveMF my for thanks Good on frontline for everyone, myelofibrosis. I'm update and in IMpactMF making

in correctly, conducted been three remember I study think, I if the sites. has

you or data Just in mentioned Faye, that at enrollment also, And of then is presentation of X Part ASH. the how wondering study. the progressing IMproveMF some

study ruxolitinib, expectations Part completed? of would as then and part, least Phase are are optimization wondering what ruxolitinib what how to X conducted you. patients weeks tolerate at study the and patients your in with be XX able to not Thank long as ruxolitinib, how far Just in the on may those that if of as of be those X the

Faye Feller

start will your for question. regarding one with Sure. the enrollment. the first I first Thanks

two correct are plan open, three we be to for And this You of there proceeding ruxolitinib. of stay levels. the and of agent anticipate that And sites on Currently, think our a that long open. with was and are will for single to questions therapy patients one at various answer a escalation options is tolerated whether ruxolitinib have dose the we answer long trial is expected how dose as as regarding could and we the be as question treatment next I those intends study, the how enrollment a combination are to well. that are

Vernon Bernardino

Okay.

IMproveMF? then data expect might preliminary of in follow-up to XXXX from Just we what kind

Faye Feller

We anticipate preliminary data. safety

John Scarlett

Yes.

is that we probably early think, signals, related is see study. talk Obviously, this we interesting efficacy if about an to I it phase will mostly safety.

a have And the can two do that. able works will we we be of critical of dose obviously, combined. and But it hope that will question So Faye go study, so is where a just it we great as drugs escalate dose to the have whether how to be dose. It and we is element is finding see it open then does an as out. said,

Vernon Bernardino

possibilities Okay, MF question. in thank line you. thank for taking I’m the front my imetelstat very interested you

John Scarlett

Thanks Vernon.

Operator

Aron questions further no to are back Feingold call closing for remarks. over time. There at the this will turn I

Aron Feingold

Thanks time today so participate. much, everyone for the Thank well taking dial-in and questions. us for you and really your to joining We appreciate you. Be everyone.

Operator

today’s concludes conference call. This

You may now disconnect.

Geron (GERN) 3 Nov 222022 Q3 Earnings call transcript